Mycobacterium avium ss paratuberculosis-associated diseases: Piecing the Crohn's puzzle together

Journal of Clinical Gastroenterology

Volumn 46, Issue 8, 2012, Pages 649-655

  Gitlin, Laura ^a   Borody, Thomas Julius ^b   Chamberlin, William ^c   Campbell, Jordana ^b  

^a Gastroenterology Institute   (United States)

^b Centre for Digestive Diseases   (Australia)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Crohn's Disease; Koch's postulates; Mycobacterium avium paratuberculosis

Indexed keywords

CLARITHROMYCIN; CLOFAZIMINE; CORTICOSTEROID; RIFABUTIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CROHN DISEASE; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENTERITIS; HELICOBACTER PYLORI; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; IN SITU HYBRIDIZATION; MYCOBACTERIUM AVIUM; MYCOBACTERIUM PARATUBERCULOSIS; NONHUMAN; PARATUBERCULOSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; CATTLE; CROHN DISEASE; HUMANS; MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS; PARATUBERCULOSIS;

EID: 84865469648     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31825f2bce     Document Type: Review

References (114)

1. Sartor RB. Does Mycobacterium avium subspecies paratuberculosis cause Crohn's Disease? Gut. 2005;54:896-898.
2. Prantera C. Mycobacteria and Crohn's Disease: The endless story. Digest Liver Dis. 2007;39:452-454.
3. Quirke P. Antagonist: Mycobacterium avium subspecies paratuberculosis is a cause of Crohn's Disease. Gut. 2001;49:757-760.
4. Behr M, Kapur V. The evidence for Mycobacterium paratuberculosis in Crohn's Disease. Curr Opin Gastroenterol. 2008;24:17-21.
5. Sartor RB. Bacteria in Crohn's Disease: Mechanisms of inflammation and therapeutic implications. J Clin Gastroenterol. 2007;41(suppl 1):S37-S43.
6. Joshi YK. Helicobacter pylori infection: Current status. J Indian Acad Clin Med. 2000;5:148-155.
7. Mendoza JL, San-Pedro A, Culebras E, et al. High prevalence of viable Mycobacterium avium subspecies paratuberculosis in Crohn's disease. World J Gastroenterol. 2010;16:4558-4563.
8. Hermon-Taylor J, Barnes N, Clarke C, et al. Mycobacterium paratuberculosis cervical lymphadenitis, followed five years later by terminal ileitis similar to Crohn's disease. BMJ. 1998;316:449-453.
9. Scanu AM, Bull TJ, Cannas S, et al. Mycobacterium avium subspecies paratuberculosis infection in cases of irritable bowel syndrome and comparison with Crohn's Disease and Johne Disease: Common neural and immune pathogenicities. J Clin Microbiol. 2007;45:3883-3890.
10. Burke Cm, Healy TM. Sarcoidosis and tuberculosis: variable immunologically determined reactions to a common cause? Irish J Med Sci. 1988;157:39-44.
11. Campbell J, Borody TJ, Leis S. The many faces of Crohn's Disease: latest concepts in etiology. Open J Int Med. 2012. (In press).
12. Schwartz K. Ueber penetriende Magen-imf Jejunalgeschwuer. Bitrage Klin Chir. 1910;68:96-111.
13. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-429.
14. Al-Orainey IO. Diagnosis of latent tuberculosis: Can we do better? Ann Thorac Med. 2009;4:5-9.
15. Gale G. Tuberculosis of the superficial lymph nodes. Can Med Assoc J. 1953;69:303-309.
16. Basgoz N. Clinical manifestations; diagnosis; and treatment of miliary tuberculosis. UpToDate. 2010.
17. Leung A. Pulmonary tuberculosis: The essentials. Radiology. 1999;210:307-322.
18. Rock RB, Olin M, Baker CA, et al. Central nervous system tuberculosis: Pathogenesis and clinical aspects. Clin Microbiol Rev. 2008;21:243-261.
19. Lamba H, Byrne M, Goldin R, et al. Tuberculosis of the cervix: Case presentation and a review of the literature. Sex Transm Infect. 2002;78:62-63.
20. Patnaik MM, Deshpande AK. Diagnosis - Addison's Disease secondary to tuberculosis of the adrenal glands. Clin Med Res. 2008;6:29.
21. Edington JW, Guest D. Study of tubercle bacilli isolated from cases of surgical tuberculosis (chiefly bone and joint) in the Sheffield area. J Hyg. 1926;25:109-118.
22. Borody TJ, George LL, Brandl S, et al. Helicobacter pylorinegative duodenal ulcer. Am J Gastroenterol. 1991;86:1154-1157.
23. Koch R. Die Aetiologie der tuberkulose. Mittheilungen aus dem Kaiserlichen Gesundheitsamte. 1884;2:1-88.
24. Van Kruiningen HJ, Chiodini RJ, Thayer WR, et al. Experimental disease in infant goats induced by a Mycobacterium isolated from a patient with Crohn's disease. A preliminary report. Dig Dis Sci. 1986;31:1351-1360.
25. Fredericks DN, Relman DA. Sequence-based identification of microbial pathogens: A reconsideration of Koch's Postulates. Clin Microbiol Rev. 1996;9:18-33.
26. Chamberlin W, Borody T, Naser S. MAP-associated Crohn's disease MAP, Koch's postulates, causality and Crohn's disease. Dig Liver Dis. 2007;39:792-794.
27. Hanauer SB. More likely than not. Nat Clin Prac Gastroenterol Hepatol. 2007;4:469.
28. Selby W, Pavli P, Crotty B. Author reply. Gastroenterol. 2007;133:1745-1746.
29. Koch R. Die aetiologie de tuberculose. Berliner Klinische Wochenschrift. 1882;19:221-230.
30. Marshall BJ, Armstrong JA, McGechie DB, et al. Attempt to fulfill Koch's postulates for pyloric Campylobacter. Med J Aust. 1985;142:436-439.
31. St Jean G. Treatment of clinical paratuberculosis in cattle. Vet Clin N Am Food A Prac. 1996;12:417-430.
32. Oki NO, Motsinger-Reif AA, Antas PRZ, et al. Novel human genetic variants associated with extrapulmonary tuberculosis: A pilot genome wide association study. BMC Res Notes. 2011;4:28-38.
33. Russell RK, Wilson DC, Satsangi J. Unravelling the complex genetics of inflammatory bowel disease. Arch Dis Child. 2004;89:598-603.
34. Shoda R, Matsueda K, Yamato S, et al. Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am J Clin Nutr. 1996;63:741-745.
35. Nugent FW, Richmond M, Park S. Crohn's Disease of the duodenum. Gut. 1977;18:115-120.
36. Malleson P. Isolated gastroduodenal Crohn's Disease in a ten-year-old girl. Postgrad Med J. 1980;56:294-296.
37. Johne HA, Forthingham L. Ein eigenthumlicher Fall von Tuberculose beim Rind [A peculiar case of tuberculosis in a cow]. Deutsche Zeitschrift fur Tiermedizin und vergleichende Pathologie. 1895;21:438-455.
38. Dalziel TK. Chronic intestinal enteritis. BMJ. 1913;2: 1068-1070.
39. Feller M, Huwiler K, Schoepfer A, et al. Long-term antibiotic treatment for Crohn's Disease: systematic review and metaanalysis of placebo-controlled trials. Clin Infect Dis. 2010; 50:473-480.
40. Chiodini RJ. Crohn's Disease and the Mycobacterioses. Clin Microbiol Rev. 1989;2:90-117.
41. Borody TJ, Bilkey S, Wettstein AR, et al. Anti-mycobacterial therapy in Crohn's Disease heals mucosa with longitudinal scars. Dig Liver Dis. 2007;39:438-444.
42. Chamberlin W, Ghobrial G, Chehtane M, et al. Successful treatment of a Crohn's Disease patient infected with bacteremic Mycobacterium paratuberculosis. Am J Gastroenterol. 2007;102:689-691.
43. Bull TJ, McMinn EJ, Sidi-Boumedine K, et al. Detection and verification of Mycobacterium avium subsp. paratuberculosis in fresh ileocolonic mucosal biopsy specimens from individuals with and without Crohn's disease. J Clin Microbiol. 2003;41:2915-2923.
44. Autschbach F, Eisold S, Hinz U, et al. High prevalence of Mycobacterium avium subspecies paratuberculosis IS900 DNA in gut tissues from individuals with Crohn's disease. Gut. 2005;54:944-949.
45. Schwartz D, Shafran I, Romero C, et al. Use of short-term culture for identification of Mycobacterium avium subsp. paratuberculosis in tissue from Crohn's disease patients. Clin Microbiol Infect. 2000;6:303-307.
46. Naser S, Ghobrial G, Romero C, et al. Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's Disease. Lancet. 2004;364: 1039-1044.
47. Nunić N, Mić ić R, Popović M, et al. Generalized miliary tuberculosis during immunosuppressive therapy. Srp Arh Celok Lek. 1981;109:527-538.
48. Fortune S, Rubin E. The complex relationship between Mycobacteria and macrophages: it's not all bliss. Cell Host Microbe. 2007;2:5-6.
49. Athreya SPK. Azathioprine in controlling type 2 reactions in leprosy: A case report. Leprosy Rev. 2007;78:290-292.
50. Beran V, Havelkova M, Kaustova J, et al. Cell wall deficient forms of mycobacteria: A review. Vet Med. 2006;7:365-389.
51. Greenstein R, Su L, Haroutunian V, et al. On the action of methotrexate and 6-mercaptopurine on M. avium subspecies paratuberculosis. Plos One. 2007;2:e161.
52. Shin S, Collins M. Thiopurine drugs azathioprine and 6- mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. Antimicrob Agents Chemother. 2008;52:418-426.
53. Van den Brande J, Braat H, Van den Brink G, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's Disease. Gastroenterology. 2003;124:1774-1785.
54. Catrina AL, Trollmo C, Klint E, et al. Evidence that antitumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages but not lymphocytes in rheumatoid arthritis joints: Extended report. Arthritis Rheum. 2005;52:61-72.
55. Bach H, Rosenfeld G, Bressler B. Treatment of Crohn's Disease patients with infliximab is detrimental for the survival of Mycobacterium avium ssp. paratuberculosis within macrophages and shows a remarkable decrease in the immunogenicity of mycobacterial proteins. J Crohn's Colitis. 2012;6: 628-629.
56. Olsen I, Tollefsen S, Aagaard C, et al. Isolation of Mycobacterium avium subspecies paratuberculosis reactive CD4 T cells from intestinal biopsies of Crohn's Disease patients. PloS One. 2009;4:e5641.
57. Ebert E, Bhatt B, Liu S, et al. Induction of suppressor cells by Mycobacterium paratuberculosis antigen in inflammatory bowel disease. Clin Exp Immunol. 1991;83:320-325.
58. Juste R, Elguezabel N, Pavon A, et al. Association between Mycobacterium avium subsp. paratuberculosis DNA in blood and cellular and humoral immune response in inflammatory bowel disease patients and controls. Int J Infect Dis. 2009;13:247-254.
59. Ren Z, Turton J, Borody T, et al. Selective Th2 pattern of cytokine secretion in Mycobacterium avium subsp. Paratuberculosis infected Crohn's Disease. J Gastroenterol Hepatol. 2008;23: 310-314.
60. Sibarue S, Keohane J, Scully P, et al. Disturbed cytokine response to Mycobacterium avium subspecies paratuberculosis is dysregulated in Crohn's Disease. Gastroenterol. 2006;130: A-240.
61. De Almeida D, Colvin C, Coussens P. Antigen-specific regulatory T cells in bovine paratuberculosis. Vet Immunol Immunopathol. 2008;125:234-245.
62. Lybeck KR, Storset AK, Olsen I. Neutralisation of IL-10 from CD14+ monocytes enhances gamma interferon production in peripheral blood mononuclear cells from Mycobacterium avium subsp. paratuberculosis infected goats. Clin Vaccine Immunol. 2009;16:1071-1412.
63. Cucino C, Sonnenberg A. Occupational mortality from inflammatory bowel disease in the United States 1991-1996.
64. Am J Gastroenterol. 2001;96:1101-1105.
65. Radon K, Windstetter D, Poluda AL, et al. Contact with farm animals in early life and juvenile inflammatory bowel disease: A case-control study. Pediatrics. 2007;120: 354-361.
66. Chiodini RJ, Thayer WR, Couta JA. Presence of Mycobacterium paratuberculosis antibodies in animal healthcare workers. P Fifth Internat Colloq Para. 1996;324-328.
67. Hermon-Taylor J. Mycobacterium avium subspecies paratuberculosis, Crohn's Disease and the doomsday scenario. Gut Pathoq. 2009;1:15-21.
68. Cirillo JD, Falkow S, Tompkins LS, et al. Interaction of Mycobacterium avium with environmental amoebae enhances virulence. Infect Immun. 1997;65:3759-3767.
69. Patel D, Danelishvilli L, Yamazaki Y, et al. The ability of Mycobacterium avium subsp. paratuberculosis to enter bovine epithelial cells is influenced by preexposure to a hyperosmolar environment and intracellular passage in bovine mammary epithelial cells. Infect Immun. 2006;74:2849-2855.
70. Reed WD, Eddleston WF, Mitchell CG, et al. Exposure and immunity to hepatitis-B virus in a liver unit. Lancet. 1974;303:581-583.
71. Radcliff FJ, Ferrero RL. Effect of low-dose antigen exposure on development of immunity to Helicobacter pylori infection in mice. Infect Immun. 2001;69:5186-5188.
72. Fridriksdottir V, Gunnarsson E, Sigurdarson S, et al. Paratuberculosis in Iceland: Epidemiology and control measures, past and present. Vet Microbiol. 2000;77:263-267.
73. Bjornsson S, Johannsson JH, Oddsson E. Inflammatory bowel disease in Iceland, 1980-89. A retrospective nationwide epidemiologic study. Scand J Gastroenterol. 1998;33:71-77.
74. Bjornsson S, Johannsson JH. Inflammatory bowel disease in Iceland, 1990-1994: A prospective, nationwide, epidemiological study. Eur J Gastroenterol Hepatol. 2000;12:31-38.
75. Sechi LA, Scanu AM, Molicotti PM, et al. Detection and Isolation of Mycobacterium avium subspecies paratuberculosis from intestinal mucosal biopsies of patients with and without Crohn's Disease in Sardinia. Am J Gastroenterol. 2005;100:1529-1536.
76. Singh A, Singh S, Makharia G, et al. Presence and characterisation of Mycobacterium avium subsp. paratuberculosis from clinical and suspected cases of Crohn's Disease and in the healthy human population in India. Int J Infect Dis. 2008;12:190-197.
77. Kumar S, Singh S, Singh A, et al. Wildlife (Boselaphus tragocamelus) - small ruminant (goat and sheep) interface in the transmission of "Bison type" genotype of Mycobacterium avium subsp. paratuberculosis in India. Comp Immunol Microbiol Infect Dis. 2010;33:145-159.
78. Van Kruiningen HJ, Joossens M, Vermeire S, et al. Familial Crohn's disease in Belgium: Pedigrees, temporal relationships among cases, and family histories. J Clin Gastroenterol. 2007;41:583-590.
79. Achord JL, Gunn CH, Jackson JF. Regional enteritis and HLA concordance in multiple siblings. Dig Dis Sci. 1982;37: 330-332.
80. Gelfand MD, Krone Cl. Inflammatory bowel disease in a family: observations related to pathogenesis. Ann Intern Med. 1970;72:903-907.
81. Bennett RA, Rubin PH, Present DH. Frequency of inflammatory bowel disease in offspring of couples both presenting with inflammatory bowel disease. Gastroenterology. 1991;100:1638-1643.
82. Allan RN, Pease P, Ibbotson JP. Clustering of Crohn's Disease in a Cotswold Village. Q J Med. 1986;59:473-478.
83. Van Kruiningen HJ, Freda BA. Clustering of Crohn's Disease in Mankato, Minnesota. Inflamm Bowel Dis. 2001;7:27-33.
84. Pierce ES, Borowitz SM, Naser SA. The Broad Street pump revisited: Dairy farms and an ongoing outbreak of inflammatory bowel disease in Forest, Virginia. Gut Pathoq. 2011;3:20-24.
85. Van Kruiningen HJ, Colombel JF, Cartun RW, et al. An indepth study of Crohn's Disease in two French families. Gastroenterology. 1993;104:351-360.
86. Aisenberg J, Janowitz HD. Cluster of inflammatory bowel disease in three close college friends. J Clin Gastroenterol. 1993;17:18-20.
87. Hornick DB, Dayton CS, Bedell GN, et al. Nontuberculous mycobacterial lung disease. Substantiation of a less aggressive approach. Chest. 1988;93:550-555.
88. Gui GP, Thomas PR, Tizard ML, et al. Two-year outcomes analysis of Crohn's Disease treated with rifabutin and macrolide antibiotics. J Antimicrob Chemother. 1997;39: 393-400.
89. Lipton J, Barach D. Flawed Australian CD study does not end MAP controversy. Gastroenterology. 2007;133:1745-1746.
90. Keunstner J. Australian Crohn's antibiotic study opens new horizons. Gastroenterology. 2007;133:1743-1744.
91. Chamberlin W. Importance of the Australian Crohn's Disease antibiotic study. Gastroenterology. 2007;133:1744-1745.
92. Behr M, Hanley J. Antimycobacterial therapy for Crohn's Disease: A reanalysis. Lancet Infect Dis. 2008;8:344.
93. Shafran I, Kugler L, El-Zataari FA, et al. Open clinical trial of rifabutin and clarithromycin therapy in Crohn's Disease. Dig Liver Dis. 2002;34:22-28.
94. Borody TJ, Leis S, Warren EF, et al. Treatment of severe Crohn's disease using antimycobacterial triple therapy- approaching a cure? Dig Liver Dis. 2002;34:29-38.
95. Borody TJ, Clancy R, Wettstein AR, et al. Anti-MAP therapy in the treatment of active Crohn's Disease. J Gastroenterol Hepatol. 2005;20:A2.
96. Chamberlin W, Borody TJ, Campbell J. Primary treatment of Crohn's Disease: Combined antibiotics taking centre-stage. Expert Rev Clin Immunol. 2011;7:751-760.
97. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's Disease: The accent 1 randomised trial. Lancet. 2002;359:1541-1549.
98. Borody TJ, Leis S, Torres M. Five years continuous anti- MAP therapy for Crohn's - observation of side effects. Am J Gastroenterol. 2008;103:S454-S455.
99. Moore TJ, Cohen MR, Furberg CD, et al. Serious adverse drug events reports to the Food and Drug Administration, 1988-2005. Arch Intern Med. 2007;167:1752-1759.
100. D' Haens G, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's Disease caused by infusion of the intestinal contents in excluded ileum. Gastroenterology. 1998;114:262-267.
101. Rutgeerts P, Geboes K, Peelers M, et al. Effect of fecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet. 1991;338:771-774.
102. Harper P, Lee E, Kettlewell M, et al. Role of fecal stream in the maintenance of Crohn's colitis. Gut. 1985;26:279-284.
103. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet. 1989;1:1156-1160.
104. Eiseman B, Silen W, Bascom GS, et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44:854.
105. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: Case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2002;34:346-353.
106. Persky SE, Brandt LJ. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol. 2000;95:3283.
107. Yoon S, Brandt L. Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: A case series of 12 patients. J Clin Gastroenterol. 2010;44:562-566.
108. Silverman M, Davis I, Pillai D. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol. 2010;8:471-473.
109. Rohlke F, Surawicz C, Stollman N. Fecal flora reconstitution for recurrent Clostridium difficile infection: Results and methodology. J Clin Gastroenterol. 2010;44:567-570.
110. You DM, Franzos A, Holman RP. Successful treatment of fulminant Clostridium difficile infection with fecal bacteriotherapy. Ann Int Med. 2008;148:632-633.
111. Borody TJ, George L, Andrews P, et al. Bowel-flora alteration: A potential cure for inflammatory bowel disease and irritable bowel syndrome? Med J Aust. 1989;150:604.
112. Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet. 1989;1:164.
113. Borody TJ, Warren EF, Leis S, et al. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol. 2003;37:42-47.
114. Ramakrishnan K, Mold JW. Urinary catheters: A review. Int J Fam Prac. 2005;3. Available at: http://www.ispub.com/journal/ the-internet-journal-of- family-practice/volume-3-number-2/ urinary-catheters-a-review.html. Accessed January 19, 2012.